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The etiology of cardiomyopathy in pregnant women remains unclear. In this issue, Hilfiker-
Kleiner et al. (2007) report that a reduction in STAT3 and a concomitant increase in cathe-
psin D may be a cause of this disease. Cathepsin D generates an antiangiogenic cleavage 
product of the hormone prolactin. The authors show that an inhibitor of prolactin secretion 
may be useful in treating this disease.Heart failure can occur in pregnant 
women or up to six months after the 
birth of the baby. This potentially fatal 
disorder is referred to as peripartum 
(or postpartum) cardiomyopathy. The 
incidence varies according to coun-
try of origin, but in the United States, 
it occurs in about 1000–1300 women 
per year (see Pearson et al., 2000), 
with mortality rates between 18%–
56%. By definition, it strikes women 
with no prior history of heart dis-
ease, and surviving women may suf-
fer long-term debilitating effects and 
may require a heart transplant. Thus 
far, there has been little insight into 
the causes of pregnancy-induced 
cardiomyopathy. Potential causes 
include inflammation of the myo-
cardium (myocarditis) or activation 
of cytokines from stress. A mouse 
model of dilated cardiomyopathy—in 
which there is overexpression of the 
α subunit of the protein Gq in cardiac 
tissue—exhibits pregnancy-induced 
cardiomyopathy (Hayakawa et al., 
2003). However, it does not seem 
that this overexpression occurs in 
women with peripartum cardiomy-
opathy. In this issue of Cell, Hilfiker-
Kleiner et al. (2007) show in female 
mice and pregnant women a relation-
ship between the transcription factor 
STAT3, an antiangiogenic cleavage 
product of prolactin and peripartum 
cardiomyopathy.
During a normal pregnancy, women 
experience cardiac hypertrophy and 
reduced relaxation or diastolic func-
tion. But in most women this hyper-trophy regresses, and function returns 
to normal following childbirth. Preg-
nancy-induced hypertrophy has been 
thought to be similar to the cardiac 
growth that occurs in response to exer-
cise, but there has not been extensive 
investigation of the pathways leading 
to pregnancy-induced cardiac hyper-
trophy. Additionally, although many 
pathways have been implicated in the 
formation of new blood vessels (ang-
iogenesis), little is known about angio-
genesis in the heart during pregnancy. 
Recently, STAT3 was shown to be crit-
ical for cardiac angiogenesis (Hilfiker-
Kleiner et al., 2005). STAT3, a DNA 
binding protein that is activated by the 
interleukin (IL)-6 family of cytokines, 
has been implicated in a wide vari-
ety of biological processes, including 
inflammation, angiogenesis, and car-
diac hypertrophy. Deletion of STAT3 in 
mice results in embryonic lethality, but 
deletion in heart tissue alone results 
in loss of capillary density with age. 
In their new study, Hilfiker-Kleiner 
et al. (2007) found that female mice 
lacking STAT3 in the heart develop 
normal pregnancy-induced cardiac 
hypertrophy accompanied by a nor-
mal increase in angiogenesis. How-
ever, these mice develop pregnancy-
induced cardiomyopathy due to an 
inability to maintain the pregnancy-
induced increase in capillary density. 
STAT3 has been shown to be cardio-
protective by reducing the production 
of reactive oxygen species (Negoro et 
al., 2001). Reactive oxygen species 
can induce the expression of a wide Cell 128, Fevariety of genes, including cathepsin 
D. The authors confirmed this role for 
STAT3, as mice that lacked STAT3 in 
heart tissue had elevated reactive 
oxygen species and elevated levels of 
cathepsin D. An antiangiogenic cleav-
age product of prolactin generated by 
cathepsin D was found in women with 
peripartum cardiomyopathy. Further-
more, the authors demonstrated that 
treatment of a cohort of mice and six 
women (in a preliminary clinical trial) 
exhibiting peripartum cardiomyopathy 
with a drug that blocks the secretion 
of prolactin (bromocriptine) reduced 
mortality.
Where does prolactin fit into these 
observations? Prolactin is a hormone 
made by the pituitary and is produced 
in both men and women. The amount 
of circulating prolactin increases late 
in pregnancy and is known to activate 
STAT3 (Cataldo et al., 2000). Prol-
actin has been implicated in >300 
biological processes, including milk 
production, immune regulation, and 
reproduction. Some of this diversity 
in function may be due to the multiple 
forms of prolactin, which have distinct 
activities. For example, full-length 
prolactin is thought to have proang-
iogenic activities, whereas the 16 kDa 
cleavage product has potent antian-
giogenic and proapoptotic activities 
(Corbacho et al., 2002). As Hilfiker-
Kleiner et al. (2007) demonstrate, the 
16 kDa cleavage product is clearly 
a major contributor to pregnancy-
induced cardiomyopathy. However, 
the 16 kDa form of prolactin has bruary 9, 2007 ©2007 Elsevier Inc. 437
been shown to inhibit tumor growth 
via its antiangiogenic activity. Para-
doxically, expression of cathepsin D 
(which cleaves prolactin) is positively 
associated with tumor metastasis 
(see Corbacho et al., 2002). There-
fore, inhibiting prolactin secretion 
may have a variety of consequences. 
However, if bromocriptine were used 
to treat peripartum cardiomyopathy, 
it would only be administered for a 
short period of time and therefore 
may not affect long-term health.
An obvious question that arises 
from this study is, will all or most 
women with peripartum cardiomyop-
athy have an etiology that involves 16 
kDa prolactin? There is a single report 
of peripartum cardiomyopathy in the 
literature in a woman who had ele-
vated levels of prolactin, but that was 
observed over 20 years ago (Matharu 
and Oelbaum, 1984). In the current 
study (Hilfiker-Kleiner et al., 2007), the 
16 kDa form of prolactin was found in 
serum from three out of five lactating 
mothers with pregnancy-induced car-
diomyopathy, and there was a marked 
decrease in STAT3 and increase in 
cathepsin D in all five samples of heart 
tissue examined. Although these find-
ings are interesting, further studies 
with a larger number of patients are 
certainly required.
How specific are the observa-
tions of Hilfiker-Kleiner et al. (2007) 
to pregnancy-induced cardiomy-
opathy? Although prolactin may be 
specific to pregnancy, other com-
ponents discussed here seem likely 438 Cell 128, February 9, 2007 ©2007 Elto be involved in other forms of car-
diac hypertrophy and heart failure. 
Upregulation of cathepsin D has 
been demonstrated in a hamster 
model of cardiac failure but is not 
altered in exercise-induced cardiac 
hypertrophy (Salminen and Vihko, 
1983). This observation is consistent 
with cathepsin D activation being a 
general marker in different cardiac 
pathologies. However, activation of 
STAT3 has been observed in hearts 
of patients with dilated cardiomy-
opathy (Ng et al., 2003), suggesting 
that a reduction of STAT3 may be a 
more specific marker of pregnancy-
induced cardiomyopathy. It will be 
interesting to determine whether 
there are single nucleotide polymor-
phisms (SNPs) in the human genome 
that reduce the levels of STAT3 in the 
heart and if those individuals carry-
ing such SNPs exhibit a general defi-
ciency in cardiac capillary density.
There are many animal models of 
cardiac hypertrophy and heart failure 
that will need to be examined to see 
whether they have the same molecular 
mechanisms as pregnancy-induced 
cardiomyopathy. Such studies will be 
an important addition to the intrigu-
ing results of Hilfiker-Kleiner et al. 
(2007) and the very encouraging data 
they have obtained with bromocrip-
tine, a drug that has been used for 
a number of years to treat individu-
als with abnormally high levels of 
prolactin. Hopefully, a larger-scale 
clinical trial of bromocriptine to treat 
pregnancy-induced cardiomyopathy sevier Inc.will be launched in the not-too-dis-
tant future. This will be of tremen-
dous value both to women suffering 
from peripartum cardiomyopathy for 
the first time and to those who have 
survived a single bout of this disease 
and who have been counseled not to 
have additional pregnancies.
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